Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Sterns

<< Previous

Bullboard Posts

Next >>

Comment by woundedkneeon Jun 03, 2021 2:23pm

173 Views

Post# 33320255

RE:RE:Sterns

So read over today's press release and see if you can find something in it that the markets (and shareholders) were not made aware of or unexpected. Similar to many government bills that have "pork" written into them that rewards, in this case, management. Seems funny that the bit of momentum after the close two days ago has suddenly disappeared.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?